Daria HAZUDA, Merck Research Labs, Westpoint, USA
Daria Hazuda has over 20 years of experience in infectious disease drug discovery, particularly in the area of novel HIV targets. Dr Hazuda led the discovery team that identified Raltegravir, the first approved HIV-1 integrase inhibitor. She was responsible for the discovery of the first prototype inhibitors and elucidation of their biochemical and molecular mechanism of action. As Vice President at Merck and Co, she is responsible for the infectious disease research including the HIV, HCV and antibacterial programs from target discovery to post licensure clinical support. Her presentation will apply the approaches of drug discovery to developing novel interventions and testing hypothesis on the nature of HIV-1 latency in vitro.
« Go Back